Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06030232

Acronym

TACOME

Enrollment

202

Registered

2023-09-08

Start date

2024-01-15

Completion date

2024-04-15

Last updated

2024-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transarterial Radioembolization

Brief summary

Radioembolization is an established treatment option for patients with unresectable primary and secondary liver tumors. Microspheres containing 90Y are injected intraarterially to deliver a high radiation dose to the tumors. Despite of our knowledge on the effectiveness of 90Y glass microspheres in the treatment of HCC, literature data on the treatment of metastatic colorectal cancer (mCRC) patients with 90Y glass microspheres is limited. In the recent EANM guideline variable healthy liver doses are recommended for patients with mCRC with an effective tumor dose recommendation based on a study with limited number of patients. Primary objectives; Investigate effective tumor dose and safe healthy liver dose in radioembolization for colorectal cancer liver metastasis using multicompartment dosimetry Secondary objectives; Investigate dose-response and dose-toxicity relationships, time to progress, concordance between pretreatment and posttreatment dose calculations.

Interventions

DEVICETherasphere

Transarterial radioembolization

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* over 18 years old * histopathologically proven colorectal cancer diagnosis * treated with radioembolization for liver metastases with Y90 glass microspheres in lobar or segmental fashion * have follow-up data at least 6 months after radioembolization

Exclusion criteria

* no PET-CT, CT or MR of the liver within last 6 weeks prior to radioembolization. No PET-CT, CT or MR of the liver 2-4 months after radioembolization Poor image quality Previous local treatment or surgery for the liver

Design outcomes

Primary

Measure	Time frame	Description
effective tumor dose and safe healthy liver dose	3th month after treatment	Compare the mean effective tumor doses effective tumour dose (in Gy) of patients with or without response to radioembolization for colorectal cancer liver metastasis.

Secondary

Measure	Time frame	Description
dose (in Gy) -response and dose (in Gy)-toxicity relationships	6th month after treatment	Investigate dose-response and dose-toxicity relationships after transarterial radioembolization.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026